Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00882206
- Locations
- 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00878254
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- B-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Lymphoblastic Lymphoma
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateDrug: cytarabineDrug: prednisoneDrug: bortezomibDrug: pegaspargaseDrug: methotrexateDrug: etoposide phosphateDrug: cyclophosphamideBiological: filgrastimDrug: leucovorin calciumOther: laboratory biomarker analysisDrug: High Dose MTX
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00873093
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- Conditions
- Myeloid NeoplasmChildhood Acute Promyelocytic Leukemia With PML-RARA
- Interventions
- Drug: Arsenic TrioxideDrug: CytarabineOther: Diagnostic Laboratory Biomarker AnalysisDrug: IdarubicinDrug: MercaptopurineDrug: MethotrexateDrug: Mitoxantrone HydrochlorideDrug: Tretinoin
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 106
- Registration Number
- NCT00866918
- Locations
- 🇺🇸
Overlook Hospital, Summit, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine SulfateDrug: PrednisoneRadiation: Prophylactic Cranial Irradiation
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 104
- Registration Number
- NCT00866307
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
- Conditions
- Lymphoblastic LymphomaLymphoblastic Leukemia
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00866749
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2
- Registration Number
- NCT00863434
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00853008
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Clínica Teknon, Barcelona, Spain
🇪🇸Hospital de Fuenlabrada, Madrid, Spain
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 89
- Registration Number
- NCT00850382
- Locations
- 🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹Elisabethinen Krankenhaus, Linz, Austria
🇦🇹Universitätsklinikum Innsbruck, Innsbruck, Austria
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT00850304
- Locations
- 🇮🇷
Hematology-Oncology and SCT Research Center, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.